Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Delta Research Partners

Neither a doctor nor a teaching hospital

Research payments

$2,086,344

676 payments

Through program year 2025, Delta Research Partners is reported as receiving $2,086,344 in research payments, across 676 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $805,451 469
2024 Research $228,593 25
2023 Research $22,079 3
2022 Research $20,497 5
2021 Research $342,177 72
2020 Research $308,360 61
2019 Research $359,186 41

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $746,220 433 payments
  2. Braintree Laboratories, Inc. $556,034 41 payments
  3. Allergan Inc. $401,141 79 payments
  4. Intercept Pharmaceuticals, Inc. $274,278 49 payments
  5. Ipsen Bioscience Inc $38,178 30 payments
  6. GlaxoSmithKline, LLC. $31,496 10 payments
  7. Madrigal Pharmaceuticals $15,685 1 payment
  8. Boehringer Ingelheim RCV GmbH & Co KG $13,071 31 payments
  9. E.R. Squibb & Sons, L.L.C. $10,037 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $204 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $411,874 216 payments
  2. Bli4900-301 $350,818 20 payments
  3. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $332,418 216 payments
  4. 1009742 $204,544 32 payments
  5. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $202,466 20 payments
  6. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $138,429 1 payment
  7. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $86,202 16 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $71,511 11 payments
  9. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $43,553 12 payments
  10. A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) $38,178 30 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record